Possible role of metabolite in flosequinan-related mortality.
Kamali
F
F
Wolfson Unit of Clinical Pharmacology, University of Newcastle upon Tyne, England.
Edwards
C
C
D000328:Adult; D000368:Aged; D000375:Aging; D001711:Biotransformation; D006333:Heart Failure / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D007674:Kidney Diseases / Q000150:complications; D008107:Liver Diseases / Q000150:complications; D008136:Longevity; D008297:Male; D011446:Prospective Studies; D011804:Quinolines / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use
D011804:Quinolines; D014665:Vasodilator Agents; C047316:flosequinan